Detalhe da pesquisa
1.
Formulation design and evaluation of liposomal sepantronium bromide (YM155), a small-molecule survivin suppressant, based on pharmacokinetic modeling and simulation.
Pharm Res
; 32(1): 238-47, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25033765
2.
Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin.
Mol Cell Proteomics
; 11(7): M111.013243, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22442257
3.
Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.
Biol Pharm Bull
; 36(12): 1921-7, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24432379
4.
Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression.
Biochem Biophys Res Commun
; 425(4): 711-6, 2012 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-22842455
5.
Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab.
J Pharmacol Exp Ther
; 343(1): 178-83, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22787117
6.
Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.
Cancer Sci
; 102(3): 614-21, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21205082
7.
YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
Anticancer Drugs
; 22(5): 454-62, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21389848
8.
YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
Cancer Res
; 67(17): 8014-21, 2007 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17804712
9.
YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
Int J Oncol
; 32(3): 545-55, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18292931
10.
Hes1 and Hes5 control the progenitor pool, intermediate lobe specification, and posterior lobe formation in the pituitary development.
Mol Endocrinol
; 21(6): 1458-66, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17426285
11.
Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [11C]YM155.
Nucl Med Biol
; 64-65: 41-46, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30041149
12.
The proneural bHLH genes Mash1, Math3 and NeuroD are required for pituitary development
J Mol Endocrinol
; 61(3): 127-138, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30307165
13.
Hes1 and Hes5 are required for differentiation of pituicytes and formation of the neurohypophysis in pituitary development.
Brain Res
; 1625: 206-17, 2015 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26348989
14.
Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
Clin Cancer Res
; 20(7): 1814-22, 2014 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24486595
15.
Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant.
Eur J Pharm Biopharm
; 88(1): 283-9, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24993306
16.
Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma.
Leuk Res
; 37(9): 1156-61, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23746965
17.
Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model.
Nucl Med Biol
; 40(2): 221-6, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23141550
18.
Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.
Mol Cancer Ther
; 11(1): 204-13, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22075159
19.
Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter.
Int J Biochem Mol Biol
; 3(2): 179-97, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22773958
20.
Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.
Leuk Res
; 35(6): 787-92, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21237508